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Peroxisome proliferator-activated receptors (PPAR α, β/δ and γ) play a key role in metabolic regulatory processes and gene
regulation of cellular metabolism, particularly in the cardiovascular system. Moreover, PPARs have various extra metabolic roles,
in circadian rhythms, inﬂammation and oxidative stress. In this review, we focus mainly on the eﬀects of PPARs on some
thermodynamic processes, which can behave either near equilibrium, or far-from-equilibrium. New functions of PPARs are
reported in the arrhythmogenic right ventricular cardiomyopathy, a human genetic heart disease. It is now possible to link the
genetic desmosomal abnormalitiy to the presence of fat in the right ventricle, partly due to an overexpression of PPARγ.M o r e o v e r ,
PPARs are directly or indirectly involved in cellular oscillatory processes such as the Wnt-b-catenin pathway, circadian rhythms
of arterial blood pressure and cardiac frequency and glycolysis metabolic pathway. Dysfunction of clock genes and PPARγ may
lead to hyperphagia, obesity, metabolic syndrome, myocardial infarction and sudden cardiac death, In pathological conditions,
regulatoryprocessesofthecardiovascularsystemmaybifurcatetowardsnewstates,suchasthoseencounteredinhypertension,type
2 diabetes, and heart failure. Numerous of these oscillatory mechanisms, organized in time and space, behave far from equilibrium
and are “dissipative structures”.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs α, β/δ,
and γ) were initially identiﬁed for their key role in metabolic
regulatory processes, in the gene regulation of cellular lipid
metabolism [1], particularly in heart muscle. PPARα is
expressed at relatively abundant levels in the heart and
activates numerous genes involved in cellular fatty acid (FA)
uptake and oxidation. The functional and biological roles
of PPARα include regulation in mitochondrial FA-oxidation,
and lipoprotein assembly and transport [1–4]. Numerous
papers have reported their complex metabolic interplay in
several cardiovascular diseases (cardiac hypertrophy, heart
failure) [5–9]. In the cardiovascular system, however, PPARs
have various extra metabolic roles, for example, in inﬂam-
mation, oxidative stress, extracellular matrix remodeling
and circadian rhythms [10]. The present paper focuses in
particular on: (i) new functions of PPARs in human heart
diseases such as arrhythmogenic right ventricular cardiomy-
opathy (ARVC) [11],ageneticcardiacdiseasewhichpresents
mutations of the desmosomal proteins, and (ii) particular
properties of PPARs directly or indirectly involved in cellular
oscillatory processes such as the Wnt pathway-β-catenin and
circadian rhythms of arterial blood pressure and cardiac
frequency. Oscillatory phenomena have also been described
intheglycolysismetabolicpathwayinwhichPPARsinterfere.
In their pioneering study, Goldbeter and Lefever [12]
have shown that the allosteric phosphofructokinase enzyme
generates far-from-equilibrium chemical oscillations [13–
15]. Moreover, PPAR dysfunction generates inﬂammatory
phenomena and free radicals for which myosin heads are
a new target [16] and the peroxydase enzyme has been2 PPAR Research
found to induce oscillatory processes [17]. Finally, the heart
is an open system that exchanges matter and energy with
its environment and may operate either near equilibrium
or, when myosin crossbridge kinetics become nonlinear in
nature [18], far from equilibrium. The lack of PPARα in
the PPARα−/− mouse model increases the distance from
equilibrium in skeletal and cardiac muscles [19].
In this paper, we focus mainly on the eﬀects of PPARs
on some thermodynamic processes, which can behave near
equilibrium, possibly in stationary state if the thermody-
namic ﬂow linearly varies with the thermodynamic force
[14]. Other systems lead to oscillatory behavior or unsta-
ble states belonging to the family of far-from-equilibrium
dissipative structures [13, 20]. They are nonequilibrium
thermodynamic systems that operate far from thermo-
dynamic equilibrium and generate order spontaneously
by exchanging energy, matter, and/or entropy with their
externalenvironment.Dissipativestructuresincludephysical
processes (whirlpools, cyclones and hurricanes), chemical
reactions (B´ enard cell convection, the Belousov-Zhabotinsky
reaction), biological systems (Turing structures, chirality,
circadian rhythms), vegetation self-organization, lasers, and
at the most sophisticated level, life itself [14, 21, 22].
2.PPARs andARVC
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a rare human disease (1/5000) characterized by a unique
histological hallmark consisting of a progressive ﬁbrofatty
replacement of the right ventricular (RV) myocardium,
together with frequent, mostly ﬁbrotic, left ventricular
(LV) involvement [23, 24]. This disease is responsible
for unexpected syncope or sudden death due to severe
ventricular arrhythmias of RV origin, typically occurring
under conditions of stress in apparently healthy young
people [25]. Diagnosis of the disease is diﬃcult in the
early stages and is based on internationally deﬁned criteria
[26]. With time, cardiac dysfunction may develop, initially
located at the RV and becoming biventricular in at least
20% of cases [27]. At the ﬁnal stage, heart transplantation
remains the only solution available. ARVC is most often
a family-related disease with autosomal dominance and
75% male penetrance, while rare autosomal-recessive forms
associated with cardiocutaneous syndromes have also been
described. Genetic mutations have been identiﬁed in about
50% of cases, mostly due to either a single alteration
or a combination of two mutations occurring among the
ﬁve desmosomal proteins so far identiﬁed in the ven-
tricular cardiomyocyte: desmoglein 2 (DSG2), desmocollin
2 (DSC2), plakophilin 2 (PKP2), plakoglobin (JUP) and
desmoplakin (DSP) [28, 29]. Because ARVC is a speciﬁc
humandisease,acomprehensiveapproachtothestudyofthe
underlying molecular mechanisms has been hampered until
recently, when genetically engineered mouse models became
available. On the other hand, PPAR abnormalities have been
reported in ARVC [11] with an increase in PPAR γ and a
decrease in PPARα in the right ventricle. The link between
PPAR dysfunction and desmosomal genetic mutations is
beginning to be understood via the Wnt/β-catenin pathway.
It has long been shown that β-catenin plays a pivotal role
during epithelial-mesenchymal transition (EMT), a funda-
mental phenomenon that characterizes normal embryonic
development, tissue regeneration and cancer proliferation
(for more details see the paper in [30]). Together with
cadherins and α-catenin, β-catenin is a normal constituent
ofthezonulaadherens,amajorcell-to-celladhesioncomplex
in pavement-like tissues. During EMT, the loss of cadherins
duetoproteasesdisruptsthezonulaadherens,thusliberating
β-catenin in the cytoplasm. This molecule then migrates
to the cell nucleus where it activates the Wnt/β-catenin
target genes, initiating the EMT phenomenon: the cells now
disrupted from the pavement become more motile and
receive mesenchymal properties with high plasticity that
enables them to migrate through the basement membrane of
the epithelium, thus becoming invasive. The key mechanism
in this process is the canonical Wnt pathway. In the absence
of a Wnt ligand, the free β-catenin becomes phosphorylated
in a destruction complex involving axin and other molecules
and is ﬁnally degraded in the proteasome. Conversely, in
the presence of a Wnt ligand, the β-catenin degradation
complex is inactivated, with recruitment of axin to the
plasma membrane, thus stabilizing nonphosphorylated β-
catenin which translocates to the nucleus; β-catenin binds to
Tcf/Leftranscriptionfactors.Theresultingcomplexbecomes
active by displacing Grouchos, leading to activation of
numerous target genes. In the myocyte, the net eﬀect is
synthesis of contractile protein. Importantly, the canonical
Wnt-β-catenin-PPARγ system has been shown to determine
the molecular switching of osteablastogenesis versus adipo-
genesis [31]. PPARγ is a prime inducer of adipogenesis that
inhibits osteoblastogenesis. Two diﬀerent pathways switch
the cell-fate decision from adipocytes to osteoblasts by sup-
pressing the transactivation function of PPARγ. First, TNF-
alpha- or IL-1-induced TAK1/TAB1/NIK signaling cascade
attenuates PPARγ-mediated adipogenesis by inhibiting the
binding of PPARγ to the DNA response element. Second,
the noncanonical Wnt pathway acts through the CaMKII-
TAK1/TAB2-NLK signaling cascade. Wnt-5a-induced phos-
phorylation of NLK triggers synthesis of a complex with the
histone methyltransferase SETDB1. This complex represses
PPARγ transactivation through histone H3-K9 methylation
at the target gene, inhibiting adipogenesis.
The Wnt-β-catenin pathway appears to be a similar
mechanism for desmosomal abnormalities in ARVC and for
some oscillatory processes. A major progress in understand-
ing the molecular mechanisms involved in ARVC has been
made by Garcia-Gras et al. [32]. The Wnt/β-catenin canoni-
cal pathway has been shown to play a role in animal and cell
models in which desmosomal proteins are genetically modi-
ﬁed. link genetic desmosomal abnormalities to the presence
of fat in the right ventricle of ARVC patients, due to dys-
function of PPARγ and α. Suppressing DSP expression leads
to nuclear translocation of the desmosomal plakoglobin
(or γ-catenin) by disruption of weakened desmosomes.
Garcia-Gras et al. have observed a 2-fold reduction in
canonical Wnt/β-catenin signaling through Tcf/Lef nuclear
transcription factors, a major pathway for contractile protein
synthesis. This helps explain the phenotype of ARVC inPPAR Research 3
humans and makes it possible to link genetic desmosomal
abnormalities to the presence of fat in the right ventricle
of ARVC patients, due to dysfunction of PPARγ and α.
Other earlier studies have shown that disruption of Wnt/β-
catenin signaling causes transdiﬀerentiation of myoblasts
into adipocytes in vitro [33] and leads to activation of
PPARγ. Thus, the resulting phenotype in heterozygous
transgenic DSP-deﬁcient mice fully recapitulates the human
disease, with excess fat and ﬁbrosis in the RV myocardium,
increased myocyte apoptosis, decreased contractile pro-
teins accounting for cardiac dysfunction, and ventricular
arrhythmias. Garcia-Gras et al. have also postulated that,
because plakoglobin (or γ-catenin) and β-catenin are closely
related armadillo proteins, they interact in a competitive and
opposite manner upon nuclear localization. Indeed, Ross et
al. [33] have long established that plakoglobin-containing
Tcf/Lef transcription factor complex binding to DNA is
less eﬀective than the corresponding β-catenin complex.
Moreover, the same authors have shown that Wnt signaling
maintains preadipocytes in an undiﬀerentiated state through
inhibition of both adipogenic transcription factors, namely
CCAAT enhancer binding protein-a (C/EBPa) and PPARγ.
The fact that the Wnt-β-catenin complex is less eﬀective in
the presence of an excess of nuclear plakoglobin would result
in less inhibition of PPARγ, thus leading to fat accumulation
in the myocardium.
Recently,Lombardietal.[34]proposedthatthenetresult
of the removal of the inhibitory eﬀects of the canonical Wnt
signaling is overexpression of bone morphogenic protein 7
(BMP7) and Wnt5b, which have been clearly identiﬁed as
promoters of adipogenesis, and suppression of the expres-
sion of connective tissue growth factor (CTGF), a known
inhibitor of adipogenesis induced by PPARγ. Importantly,
the authors have also suggested that second heart ﬁeld
progenitor cells, which are the major source of RV cell
lineage during embryogenesis, could switch to adipocytes in
ARVC, thus accounting for the preferential location of the
disease on the right ventricle. On the other hand, Tandri
et al. [35] have shown that signal levels for ventricular gap
junction protein connexion-43 were diminished in ARVC
tissues, thus reinforcing the hypothesis that some other
cell-to-cell adhesion systems including gap junctions (and
plausibly zonulae adherents) could become fragile and also
disrupt as a consequence of desmosome disruption. Gap
junction disruption may in turn precipitate intracellular
calcium intrusion leading to ventricular premature beats and
severe ventricular arrhythmias.
In a recent study, Djouadi et al. [11] have shown for
the ﬁrst time that RV surviving myocytes from ARVC
was characterized by a reduction in expression of PPARα,
as compared to control hearts, together with a dramatic
activation of the PPARγ pathway, as attested by the increase
in PPARγ mRNA and protein. In contrast, the LV exhibited
no changes in PPARγ expression, as compared with controls,
whereas the expression of PPARα was reduced. Therefore,
changes in PPAR signaling may contribute to myocardium
fatty accumulation and contractile dysfunction in ARVC. In
the same study, the authors also observed heavy neutral lipid
accumulationinhumanARVCRVmyocytesattheboundary
between totally fatty transformed myocardium and optically
preserved muscle, as also noted earlier by d’Amati et al.
[36]. This observation suggests that mature RV myocytes
may be directly transformed into mature adipocytes during
evolution of the disease. Conversely, LV cardiomyocytes were
characterized by heavy ﬁbrosis and little lipid accumulation,
consistent with the lack of expression of the PPARα pathway
in the ARVC LV myocardium. Finally, it might be postulated
that whatever the desmosomal protein invalidated, the net
result in the RV would be a nuclear transfer of plakoglobin
(γ-catenin) with resulting inhibition of Wnt/β-catenin sig-
naling and PPARγ overexpression, leading to the unique
histological phenotype of ﬁbrofatty replacement and loss
of contractile protein expression which summarizes ARVC
muscle transformation. Taken as a whole, the Wnt/β-catenin
pathway appears to be involved in animal and cell models
in which desmosomal proteins are genetically modiﬁed [32].
This helps explain the phenotype of ARVC in humans and
makes it possible to link genetic desmosomal abnormalities
to the presence of fat in the right ventricle of ARVC patients,
due to dysfunction of PPARγ and α [11].
Moreover, the Wnt/β-catenin pathway through oscilla-
tory processes have recently been described in the somite
formation [37]. From a thermodynamic point of view,
these oscillatory mechanisms are of major importance
[22] because they behave far from equilibrium leading to
dissipative structures discovered by Prigogine and colleagues
[20, 38].
3.PPARs, CardiovascularSystem,and
Circadian Clock
The cardiovascular system is inﬂuenced by numerous
extracellular stimuli in a time-of-day-dependent manner
[39]. Among the main environmental ﬂuctuations are
light, temperature, nutrients and humidity. The myocardial
metabolism also exhibits diurnal variations. An intramy-
ocardial circadian clock, whichrepresents a cell-autonomous
molecular mechanism, regulates the myocardial metabolism
either directly (via triglyceride and glycogen metabolism) or
indirectly (via modulation of the myocardium function in
response to changes in workload, insulin secretion, and fatty
acid supply). This intramyocardial circadian clock makes
it possible to anticipate changes in environmental stimuli,
that is, changes in workload or feeding status prior to their
onset. Disruption of the circadian clock may impair the
synchronization between the myocardium and its environ-
ment and may result in pathogenesis such as observed in
diabetes mellitus. Generally, environmental factors ﬂuctuate
in a predictable manner (light/dark cycles), others are less
predictable (feeding/fasting cycles). They also depend either
onthetimeofday(i.e.,circadian)oryear(i.e.,seasonal).The
primary timekeeping mechanism [40] is the intracellular cir-
cadian clock [41–43]. Circadian clocks are cell-autonomous
molecular mechanisms and are transcriptionally-based pos-
itive and negative feedback loops with a free running period
of about 24 hours. Mammalian circadian clock mecha-
nisms involve two critical transcription factors, CLOCK4 PPAR Research
and BMAL1 [44, 45]. CLOCK/BMAL1 heterodimerization
leads to formation of both positive (BMAL1) and negative
(PER1/2/3, CRY1/2, rev-erb-alpha, DEC1/2) loops, the latter
repressingthetranscriptionalactivityoftheCLOCK/BMAL1
heterodimer. The CLOCK/BMAL1 heterodimer also inﬂu-
ences several clock output genes, so that the circadian clock
may alter the cellular function over the course of the day.
Clock genes themselves link the core molecular clock and
metabolic regulatory networks. The nuclear receptor and
core clock component rev-erb-alpha behaves as a gatekeeper,
coordinating the circadian metabolic response in a timely
manner [46].
The circadian clock mechanism allows the cell to
perceive the time of day and facilitates cellular responses
to environmental stimuli in both a rapid and temporally
appropriate manner. This may confer a selective advantage
of anticipation. Circadian rhythmicities are involved in
cardiovascularphysiology(heartrate,cardiacoutput,arterial
blood pressure) and pathophysiology (arrhythmias) [47,
48]. Sleep/wake and feeding/fasting cycles are two major
physiologically environmental circadian cycles inﬂuencing
the myocardial function in its property of anticipating
metabolic processes. Contractile function is closely related
to myocardial metabolism and limitation of ATP synthesis
may impair myocardial contractile function and survival of
patients[49,50].Themyocardialmetabolismisabletoadapt
rapidly to environmental stimuli both during physiological
situations such as developmental transitions from fetal
to adult state and during pathophysiological conditions,
such as heart failure [51–53]. Importantly, over the 24-
hour period, sleep/wake and feeding/fasting cycles markedly
inﬂuence myocardium function. Periods of wakefulness
are associated with an increase in physical activity, heart
rate, cardiac output and food consumption [54, 55]. The
circadian clock within the cardiomyocyte mediates diurnal
variations in the responsiveness of the heart to increased
workload, according to contractile function and metabolic
ﬂux levels [56]. It has been found that there is a diurnal
variation in the transcriptional response of the heart to
fatty acids, which occurs in a cardiomyocyte circadian clock-
dependent manner [57, 58]. The heart responds to fatty
acid variations by activating PPARs [59]. PPARα can mediate
diurnal variations in the responsiveness of the heart to both
fatty acids and speciﬁc PPARα agonism (WY-14 643) [57].
The PPARα gene is a circadian clock-regulated gene in the
liver [60]. In the normal heart, PPAR alpha mRNA exhibits
only weak circadian oscillations. This raises the question
of the importance of the role of the PPARα gene in the
cardiomyocyte circadian clock [47, 56, 57].
Recently, it has been demonstrated that vascular PPARγ
is a peripheral regulator of cardiovascular rhythms which
controls circadian variations in blood pressure and heart rate
throughBMAL1[61].PPARγ appearstobeakeycomponent
of the vascular clock. In mice with vascular PPARγ deletion
(Tie2-Cre/ﬂox and SM22 Cre/ﬂox mice), the circadian
ﬂuctuations in heart rate and blood pressure are reduced.
Thus, circadian rhythms of blood pressure and heart rate
appear, at least partly, to be regulated by a PPARγ-dependent
mechanismwhichisperipheralandintrinsictobloodvessels.
Pioglitazone, a PPARγ activator, shifts the circadian rhythm
of blood pressure from nondipper to dipper type 2 diabetes
patients [62]. In PPARγ mutant mice, the impairment of
cardiovascular rhythmicity parallels the diurnal variations
in urinary excretion of norepinephrine and epinephrine
(estimates of the overall sympathetic tone), which are sup-
pressed [61], similarly to that observed in BMAL1−/− mice
[63] and in Cry-deﬁcient mice lacking a biological clock
[64]. As discussed by Wang and colleagues, several evidences
show that PPARγ acts as a direct regulator of BMAL1 in
blood vessels [61]; (i) a vascular PPARγ oscillation precedes
BMAL1; (ii) in blood vessels, PPARγ deﬁciency induces a
blockade of rhythmicity and baseline BMAL1 expression
in the aorta; (iii) a direct interaction between PPARγ and
BMAL1 has been demonstrated by means of a ChIP assay;
(iv) rosiglitasone induces aortic expression of BMAL1; (v) in
vascular cell, BMAL1 promotor is responsive to rosiglitasone
and this is abolished by mutagenesis at the PPRE site level.
Changes in feeding time or in photoperiod reset the phase of
rhythmic expression of vascular PPARγ.T h i ss u p p o r t sar o l e
forPPARγ asacomponentoftheperipheralclock.Themajor
role of PPARγ in glucose and lipid metabolism [65, 66]a n d
the discovery of the circadian properties of PPARγ [61]m a y
confertoPPARγacoordinatedfunctionbetweenmetabolism
and circadian rhythms. Moreover, PPARα directly interacts
with BMAL1 and regulates the peripheral hepatic oscillator
[67]. Overall, these data suggest that the peripheral clock
BMAL1 and diﬀerent PPAR subtypes interfere in a complex
manner to regulate the metabolic function of glucose and
lipid and the cardiovascular circadian rhythms of blood
pressure and heart rate. Pathophysiological consequences
of circadian dysfunctions may be important. In normal
humans, a sharp rise in blood pressure occurs before
awaking and peak values appear around midmorning.
Suddencardiacdeath,myocardialinfarctionandstrokeoften
occur at the early morning surge in blood pressure [68,
69]. BMAL1 and CLOCK dysfunction leads to hyperpha-
gia, obesity and metabolic syndrome including hyperlipi-
demia, hepatic steatosis, hyperleptinemia and hyperglycemia
[70–72].
Circadian rhythms originate from the negative feedback
which is exerted by a protein on the expression of its gene
[73, 74]. A. Goldbeter has proposed molecular models for
circadian oscillations of the period (PER) protein which
behaves as a transcriptional regulator modulating several
genes besides PER its own gene. For appropriate parameter
values of the molecular model, the steady state becomes
unstable and limit-cycle oscillations appear. These far-from-
equilibrium systems have been described as dissipative
structures[20]. As previously reported, a segmentation clock
has been demonstrated for genes involved in Wnt, Notch
andFibroblastGrowthFactor(FGF)signalingpathways[37].
The segmentation clock controls the periodic formation of
somites in vertebrate embryos and represents a complex
example of biological rhythm. This oscillatory phenomenon
combines temporal and spatial self-organization [75, 76].
Thus, the Wnt/β catenin pathway interferes in oscillatory
biological processes and modulates the PPARs, themselves
subject to rhythmic oscillations [60]. Such nonlinear systemsPPAR Research 5
favor the occurrence of instabilities and thermodynamically
exhibit far-from-equilibrium behavior.
4. PPARs, PyruvateDehydrogenase,
Phosphofructokinase, Glycolytic
Oscillations, andDissipativeStructures
PPARs play a key role in the glucose metabolic pathway
[77, 78]. Over expression of the PPARα isoform in skeletal
and cardiac muscles of mice drives diminished glucose
transporter gene expression and glucose uptake into these
insulin target tissues [79]. In heart muscle perfused with
FA and ketone bodies, the glycolytic rate is decreased.
The impairment of glucose degradation occurs at four
key steps [80], that is, membrane transport of glucose,
glucosephosphorylation,phosphofructokinaseandpyruvate
dehydrogenase complex (PDC), metabolic conditions where
PPARα is modiﬁed. Moreover, in type 2 diabetes, there is an
increased expression of PPARα and its target genes involved
infattyacidmetabolisminskeletalmuscleofZuckerDiabetic
Fatty (ZDF) rats. In contrast, the mRNA levels of genes
involved in glucose transport and utilization (GLUT4 and
phosphofructokinase) have been shown to be decreased,
whereas the expression of pyruvate dehydrogenase kinase-4
(PDK-4), which suppresses glucose oxidation, is increased
[81]. The shift from glucose to fatty acids as the source
of energy in skeletal muscle of ZDF rats is accompanied
by a decrease of subunit 1 of complex I and subunit II
of complex IV, two genes of the electronic transport chain
encoded by mtDNA, and a decrease in transcript levels of
PPARγ Coactivator 1 (PGC-1). Inhibition of PDC occurs by
activation of the PDKs after an increase in the mitochondrial
acetyl-CoA/CoA and NADH/NAD+ ratios generated by high
fatty acid oxidation rates. In the heart, PDK-4 is a target
gene for upregulation by PPARα which forces FA oxidation
by blocking pyruvate oxidation [79].
Glycolysis reactions involve glucose, ADP, NAD,
pyruvate, ATP,a n dNADH, according to the following
overall reaction:
Gl uc o se+2 ADP+2 Pi+2 N AD
⇐⇒ 2Pyruvate+2ATP+2NADH.
(1)
A reaction of the process is autocatalyzed by phospho-
fructokinase (PFK), responsible for glycolytic oscillations.
PFK, an allosteric enzyme, can lead to instabilities beyond
which a new state can be organized in time and in space
[82, 83]. This open monosubstrate enzyme is activated by
the product of the reaction. Positive feedback is responsible
for periodic behavior and glycolytic oscillations are due to
activation of PFK by its reaction product. These oscillations
were obtained in a two-variable model for the product-
activated PFK reaction responsible for glycolytic oscillations
[84, 85]. Limit-cycle oscillations represent a model of
nonequilibrium self-organization. PPARα interferes in PDK,
PDC and PFK activities and the cellular regulation of these
four proteins is inﬂuenced by circadian rhythms. These far-
from-equilibrium oscillatory mechanisms enter the ﬁeld of
dissipative structures initially described by Illia Prigogine
[12, 20].
5. PPARα Deﬁciency and Cardiac Performance
ThefunctionalandbiologicalrolesofPPARαincardiacmus-
cle have been extensively investigated through the PPARα−/−
mouse model [2, 4, 86]. Although PPARα−/− mice have a
normal life span, they develop progressive cardiac ﬁbrosis
with abnormal myoﬁbrils and mitochondria [4]. Cardiac
abnormalities have been reported in PPARα−/− mice [87,
88]. Histological studies revealed signiﬁcant cardiomyocyte
hypertrophy in PPARα−/− mice [16]. Ex vivo left ventricular
papillary muscle exhibits reduced shortening velocity and
isometric tension. The reduced in vitro myosin-based veloc-
ity in PPARα−/− heart strongly suggests that pathological
processes that directly aﬀects the myosin molecule itself
are involved in cardiac dysfunction in PPARα−/− mice
[16, 89–91]. Echocardiographic left ventricular fractional
shortening is also reduced in PPARα−/− mice [16]. From a
thermodynamic point of view, myosin II molecular motors
from PPARα−/− mouse diaphragm muscle behave in a
near-equilibrium manner and in a stationary state [19],
althoughthosefromheartmusclemightoperatefartherfrom
equilibriumthandoesdiaphragmmyosinII[16].Thiswould
be due to high values of crossbridge kinetics and low values
of crossbridge eﬃciency in mouse heart muscle [92]. The
lack of PPARα induces an increase of the distance from
equilibrium according to the type of myosin II molecular
motors.
6. PPARα, Redox Balance and Heart: Myosin II
MolecularMotor,aTargetforOxidativeStress
A balance between oxidants and antioxidant defenses is
required to maintain the homeostasis of cardiac function
[93–97]. In a physiological range, the antioxidative response
to a moderate increase in ROS may be suﬃcient to reset
the balance between ROS production and ROS scavenging
capacity [98, 99] and the relation between ROS concen-
tration and muscle performance is a bell-shaped relation-
ship. Thus redox homeostasis and muscle function can be
maintainedinanear-equilibriumstationarythermodynamic
state [14, 19] or quasi-stable state [100]. In the PPARα−/−
mouse model, the redox system is subjected to dramatic
and/or long-lasting perturbations, and cardiac dysfunction
appears with direct impairment of the myosin II heads
[16]. Depletion of antioxidant enzymes such as superox-
ide dismutase (SOD), catalase, and glutathione peroxidase
(GPX) or overproduction of reactive oxygen species (ROS)
or reactive nitrogen species (RNS), may induce oxidative
stress and cause cardiac functional disorders [97, 101].
Importantly, it has been shown that oscillations may be
induced by peroxidase [17], and the waveform of the
oscillations changes when the concentration of peroxidase is
varied. There is strong evidence that activation of PPARα is
necessary to prevent cellular oxidative damage that may
occur during physiological cellular metabolism or under6 PPAR Research
conditions of inﬂammation and oxidative stress, probably
through repressing nuclear factor-κB signaling and reducing
inﬂammatory cytokine production [102–104]. Therefore,
chronic deactivation of the PPARα signaling pathway may
upset normal equilibrium between oxidant production and
antioxidant defenses and contribute to cardiac damage.
SODs act as a ﬁrst line of defense against oxidative stress by
catalyzing the dismutation of superoxide anions to hydrogen
peroxide(H2O2).Subsequently,H2O2 isreducedtoH2Oand
O2 by peroxidase or catalase [105]. Regulation of MnSOD is
considered to play a crucial role in cardiac oxidative stress
[106, 107]. There is a decrease in MnSOD expression in
PPARα−/− hearts compared with WT, associated with an
even more pronounced decrease in enzymatic activity [16,
106, 107]. This increases the level of superoxide, which in
turn may react with the NO to form the powerful oxidant
peroxynitrite and induce protein nitration.
In heart, myoﬁbrillar [96, 108] as well as mitochondrial
[109] proteins are major targets for oxidative stress-derived
eﬀects. Changes in protein structure have been shown to
modulate cardiac function [93, 97]. Therefore, oxidative
and/or nitrosative modiﬁcations of contractile proteins may
contribute to cardiac dysfunction in PPARα−/− mice. For
example, protein tyrosine-nitration has been shown to
be involved in several cardiomyopathies [93, 97, 110]. In
PPARα−/− heart in particular, myosin heavy chain represents
a major target for protein tyrosine nitration [16]. Alterations
in the conformation of myosin II molecular motors by
nitration account for the reduced myosin-based velocity
observed in PPARα−/− heart and consequently account
for the decreased maximum unloaded shortening velocity
and total tension of left ventricular papillary muscles.
Moreover, PPARα−/− hearts exhibit a substantial increase
in HNE-protein adducts, thus attesting to increased lipid
peroxidation, which contributes to contractile alterations
[105]. Peroxynitrite may also impair myocardial contrac-
tility via other mechanisms including activation of matrix
metalloproteinases, nuclear enzyme poly (ADP-ribose) poly-
merase, induction of apoptosis in myocytes, impairment
of mitochondrial function, or abnormalities in calcium
cycling [110]. Potential sources of increased production of
superoxide in PPARα−/− heart include activation of various
enzyme complexes such as NADPH oxidase and xanthine
oxidase. Increased myocardial NO may result from diﬀerent
sources, such as increased myocardial iNOS activity [110].
Generation of peroxynitrite can trigger posttranslational
modiﬁcations of proteins such as S-glutathiolation or S-
nitrosylation as well as severe oxidative injury leading to the
induction of cell death [110].
7. Conclusion
Taken as a whole, this paper shows how PPARs in the
cardiovascular system are involved in physiological and
pathological metabolic processes and circadian rhythms,
often involving oscillatory systems modulated by complex
gene activities. These oscillatory systems behave far from
equilibrium and their concerted activities make it possible
to adapt the glucose/free fatty acids metabolism to the
cardiovascular function, according to circadian rhythms
of blood pressure and heart rate [61]. In pathological
conditions, these regulatory processes of the cardiovas-
cular system may bifurcate towards new states, such as
those encountered in hypertension, type 2 diabetes, car-
diac hypertrophy, myocardial infarction, and heart failure.
PPARα gene regulatory pathway activity is downregulated in
hypertrophied heart [111] and in the human failing heart
[111–114]. It is unclear whether the metabolic shift, with
increased reliance on glucose metabolism rather than fatty
acid oxidation, induces a protective response allowing the
heart to maintain contractile function or is the initial step
leading to progressive deterioration of contractile function
[111, 115]. Dysfunction of BMAL1, CLOCK and PPARγ may
lead to obesity and metabolic syndrome [70–72]. PPARs are
involvedinseveraloscillatorysystems(phosphofructokinase,
circadian rhythms, Wnt/β-catenin pathway, etc.). The Wnt-
β-catenin pathway, an oscillatory system involved in somite
formation, seems to help explain the pathophysiology of
ARVC in which PPARα and γ are disturbed. Prigogine and
colleagues have shown that such organized structures in time
and space behave far from equilibrium and are “dissipative
structures” [116–120].
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